Table 2.
Correlations between baseline plasma concentrations of the IL-20R cytokines and clinical parameters, response rates, and radiographic progression
| Baseline cytokine concentration | |||
|---|---|---|---|
| IL-19 | IL-20 | IL-24 | |
| Disease activity scoresa | |||
| Patient global | 0.053 (0.59) | −0.061 (0.46) | 0.029 (0.73) |
| Physician global | −0.044 (0.59) | 0.042 (0.61) | 0.067 (0.41) |
| HAQ | −0.013 (0.88) | 0.070 (0.39) | 0.084 (0.31) |
| DAS28CRP | −0.015 (0.85) | 0.030 (0.72) | 0.071 (0.38) |
| Response ratesb | |||
| ACR20 | −0.093 (0.28) | 0.038 (0.66) | 0.018 (0.83) |
| ACR 50 | −0.035 (0.69) | 0.060 (0.48) | 0.038 (0.66) |
| ACR70 | −0.016 (0.85) | 0.026 (0.76) | 0.055 (0.52) |
| ACR90 | −0.038 (0.66) | −0.021 (0.81) | −0.035 (0.68) |
| Radiographic progressionc | |||
| Total Sharp score | 0.04 (0.63) | 0.27 (0.001) | 0.23 (0.005) |
| Erosions | −0.014 (0.87) | 0.14 (0.094) | 0.17 (0.047) |
| Joint space narrowing | 0.05 (0.55) | 0.16 (0.062) | 0.10 (0.23) |
Data were analyzed using the Spearman’s correlation. Numbers indicate Spearmans Rho with P value in parenthesis. Bold numbers indicate P < 0.05. aDisease activity scores at baseline. bResponse after 12 months of treatment. cRadiographic progression after 12 months of treatment (12 months – baseline)
ACR American College of Rheumatology, DAS28CRP disease activity score 28 based on C-reactive protein, HAQ health assessment questionnaire, IL interleukin